Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Investigation of single and synergic effects of NLRC5 and PD-L1 variants on the risk of colorectal cancer

C. Catalano, MI. da Silva Filho, C. Frank, K. Jiraskova, V. Vymetalkova, M. Levy, V. Liska, O. Vycital, A. Naccarati, L. Vodickova, K. Hemminki, P. Vodicka, ANR. Weber, A. Försti,

. 2018 ; 13 (2) : e0192385. [pub] 20180206

Language English Country United States

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc18024370

Grant support
NV15-27580A MZ0 CEP Register

Constitutive activation of interferon signaling pathways has been reported in colorectal cancer (CRC), leading to a strong CD8+ T cell response through stimulation of NLRC5 expression. Primed CD8+ T cell expansion, however, may be negatively regulated by PD-L1 expression. Additionally, aberrant PD-L1 expression enables cancer cells to escape the immune attack. Our study aimed to select potential regulatory variants in the NLRC5 and PD-L1 genes by using several online in silico tools, such as UCSC browser, HaploReg, Regulome DB, Gtex Portal, microRNA and transcription factor binding site prediction tools and to investigate their influence on CRC risk in a Czech cohort of 1424 CRC patients and 1114 healthy controls. Logistic regression analysis adjusted for age and gender reported a moderate association between rectal cancer risk and two NLRC5 SNPs, rs1684575 T>G (OR: 1.60, 95% CI: 1.13-2.27, recessive model) and rs3751710 (OR: 0.70, 95% CI: 0.51-0.96, dominant model). Given that a combination of genetic variants, rather than a single polymorphism, may explain better the genetic etiology of CRC, we studied the interplay between the variants within NLRC5, PD-L1 and the previously genotyped IFNGR1 and IFNGR2 variants, to evaluate their involvement in the risk of CRC development. Overall we obtained 18 pair-wise interactions within and between the NLRC5 ad PD-L1 genes and 6 more when IFNGR variants were added. Thirteen out of the 24 interactions were below the threshold for the FDR calculated and controlled at an arbitrary level q*<0.10. Furthermore, the interaction IFNGR2 rs1059293 C>T-NLRC5 rs289747 G>A (P<0.0001) remained statistically significant even after Bonferroni correction. Our data suggest that not only a single genetic variant but also an interaction between two or more variants within genes involved in immune regulation may play important roles in the onset of CRC, providing therefore novel biological information, which could eventually improve CRC risk management but also PD-1-based immunotherapy in CRC.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18024370
003      
CZ-PrNML
005      
20180710092716.0
007      
ta
008      
180709s2018 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1371/journal.pone.0192385 $2 doi
035    __
$a (PubMed)29408916
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Catalano, Calogerina $u Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
245    10
$a Investigation of single and synergic effects of NLRC5 and PD-L1 variants on the risk of colorectal cancer / $c C. Catalano, MI. da Silva Filho, C. Frank, K. Jiraskova, V. Vymetalkova, M. Levy, V. Liska, O. Vycital, A. Naccarati, L. Vodickova, K. Hemminki, P. Vodicka, ANR. Weber, A. Försti,
520    9_
$a Constitutive activation of interferon signaling pathways has been reported in colorectal cancer (CRC), leading to a strong CD8+ T cell response through stimulation of NLRC5 expression. Primed CD8+ T cell expansion, however, may be negatively regulated by PD-L1 expression. Additionally, aberrant PD-L1 expression enables cancer cells to escape the immune attack. Our study aimed to select potential regulatory variants in the NLRC5 and PD-L1 genes by using several online in silico tools, such as UCSC browser, HaploReg, Regulome DB, Gtex Portal, microRNA and transcription factor binding site prediction tools and to investigate their influence on CRC risk in a Czech cohort of 1424 CRC patients and 1114 healthy controls. Logistic regression analysis adjusted for age and gender reported a moderate association between rectal cancer risk and two NLRC5 SNPs, rs1684575 T>G (OR: 1.60, 95% CI: 1.13-2.27, recessive model) and rs3751710 (OR: 0.70, 95% CI: 0.51-0.96, dominant model). Given that a combination of genetic variants, rather than a single polymorphism, may explain better the genetic etiology of CRC, we studied the interplay between the variants within NLRC5, PD-L1 and the previously genotyped IFNGR1 and IFNGR2 variants, to evaluate their involvement in the risk of CRC development. Overall we obtained 18 pair-wise interactions within and between the NLRC5 ad PD-L1 genes and 6 more when IFNGR variants were added. Thirteen out of the 24 interactions were below the threshold for the FDR calculated and controlled at an arbitrary level q*<0.10. Furthermore, the interaction IFNGR2 rs1059293 C>T-NLRC5 rs289747 G>A (P<0.0001) remained statistically significant even after Bonferroni correction. Our data suggest that not only a single genetic variant but also an interaction between two or more variants within genes involved in immune regulation may play important roles in the onset of CRC, providing therefore novel biological information, which could eventually improve CRC risk management but also PD-1-based immunotherapy in CRC.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a antigeny CD274 $x genetika $7 D060890
650    _2
$a studie případů a kontrol $7 D016022
650    _2
$a kohortové studie $7 D015331
650    _2
$a kolorektální nádory $x genetika $7 D015179
650    _2
$a ženské pohlaví $7 D005260
650    12
$a genetická predispozice k nemoci $7 D020022
650    _2
$a lidé $7 D006801
650    _2
$a intracelulární signální peptidy a proteiny $x genetika $7 D047908
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a jednonukleotidový polymorfismus $7 D020641
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a da Silva Filho, Miguel Inacio $u Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
700    1_
$a Frank, Christoph $u Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
700    1_
$a Jiraskova, Katerina $u Department of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Prague, Czech Republic. Institute of Biology and Medical Genetics, 1st Medical Faculty, Charles University, Prague, Czech Republic.
700    1_
$a Vymetalkova, Veronika $u Department of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Prague, Czech Republic. Institute of Biology and Medical Genetics, 1st Medical Faculty, Charles University, Prague, Czech Republic.
700    1_
$a Levy, Miroslav $u Department of Surgery, First Medical Faculty, Charles University and Thomayer Hospital, Prague, Czech Republic.
700    1_
$a Liska, Vaclav $u Department of Surgery, First Medical Faculty, Charles University and Thomayer Hospital, Prague, Czech Republic. Biomedical Center, Faculty of Medicine in Pilsen, Charles University Prague, Pilsen, Czech Republic.
700    1_
$a Vycital, Ondrej $u Department of Surgery, First Medical Faculty, Charles University and Thomayer Hospital, Prague, Czech Republic. Biomedical Center, Faculty of Medicine in Pilsen, Charles University Prague, Pilsen, Czech Republic.
700    1_
$a Naccarati, Alessio $u Department of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Prague, Czech Republic. Molecular and Genetic Epidemiology, Italian Institute for Genomic Medicine (IIGM), Turin, Italy.
700    1_
$a Vodickova, Ludmila $u Department of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Prague, Czech Republic. Institute of Biology and Medical Genetics, 1st Medical Faculty, Charles University, Prague, Czech Republic. Biomedical Center, Faculty of Medicine in Pilsen, Charles University Prague, Pilsen, Czech Republic.
700    1_
$a Hemminki, Kari $u Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany. Center for Primary Health Care Research, Clinical Research Center, Lund University, Malmö, Sweden.
700    1_
$a Vodicka, Pavel $u Department of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Prague, Czech Republic. Institute of Biology and Medical Genetics, 1st Medical Faculty, Charles University, Prague, Czech Republic. Biomedical Center, Faculty of Medicine in Pilsen, Charles University Prague, Pilsen, Czech Republic.
700    1_
$a Weber, Alexander N R $u Department of Immunology, Interfaculty Institute for Cell Biology, University of Tübingen, Tübingen, Germany.
700    1_
$a Försti, Asta $u Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany. Center for Primary Health Care Research, Clinical Research Center, Lund University, Malmö, Sweden.
773    0_
$w MED00180950 $t PloS one $x 1932-6203 $g Roč. 13, č. 2 (2018), s. e0192385
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29408916 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180709 $b ABA008
991    __
$a 20180710093006 $b ABA008
999    __
$a ok $b bmc $g 1316501 $s 1021291
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 13 $c 2 $d e0192385 $e 20180206 $i 1932-6203 $m PLoS One $n PLoS One $x MED00180950
GRA    __
$a NV15-27580A $p MZ0
LZP    __
$a Pubmed-20180709

Find record

Citation metrics

Archiving options